Administration routes / Treatment
Objectives
The evaluation of the effects of a compound requires its administration. This can be performed using various routes and frequencies. Moreover, some pathophysiological models are pharmacologically-induced and also require administration of substance(s).
Summarized methodology
- Various administrations routes can be proposed as described in figure 1.
![]() |
Figure 1: Administration routes. |
- Several administration modalities are available in conscious (restrained and unrestrained) or anesthetized animals:
- Acute: single administration
- Chronic: repeated or continuous administration (direct administration, via catheterisation, osmotic pump, in chow or drinking water)
Note: Pelvipharm staff is highly trained to every route of administration
Endpoints
- Evaluation of the effects of a compound and its vehicle on a variety of experimental pathophysiological models
- Pharmacological induction of a pathophysiological model
NB: Pelvipharm will gladly study the feasibility of additional administration routes and modalities to meet its client’s needs.
Related Pelvipharm bibliography
Oudot, A. et al.
J Sex Med (2010) : 7(1)p1:79-88
Behr-Roussel, D. et al.
Am J Hypertens (2008): 21(11):1258-1263
Clément, P. et al.
Br J Pharmacol (2008): 154(5):1150-1159
Behr-Roussel, D. et al.
Eur Urol (2008): 53(6):1272-1281
Clément, P. et al.
Neuroscience (2007): 145(2):605-610
Rossler, A.S. et al.
J Sex Med (2006) : 3:432–441
Giuliano, F. et al.
Neuroscience (2006): 138(1):293-301
Behr-Roussel, D. et al.
Eur Urol (2005) :47(1):87-91
Giuliano, F. et al.
BJU Int (2004) : 93(4):605-608
Sironi, G. et al.
J Pharmacol Exp Ther (2000): 292(3) :974-981
J Sex Med (2010) : 7(1)p1:79-88
Behr-Roussel, D. et al.
Am J Hypertens (2008): 21(11):1258-1263
Clément, P. et al.
Br J Pharmacol (2008): 154(5):1150-1159
Behr-Roussel, D. et al.
Eur Urol (2008): 53(6):1272-1281
Clément, P. et al.
Neuroscience (2007): 145(2):605-610
Rossler, A.S. et al.
J Sex Med (2006) : 3:432–441
Giuliano, F. et al.
Neuroscience (2006): 138(1):293-301
Behr-Roussel, D. et al.
Eur Urol (2005) :47(1):87-91
Giuliano, F. et al.
BJU Int (2004) : 93(4):605-608
Sironi, G. et al.
J Pharmacol Exp Ther (2000): 292(3) :974-981

Links to applicable Targeted disorders / Pathophysiological models
- Atherosclerosis
- BPH (Benign Prostatic Hyperplasia)
- Diabetes
- ED (Erectile Dysfunction)
- Ejaculatory disorders (premature or delayed ejaculation / anejaculation)
- FSD (Female Sexual Dysfunction)
- Hypertension
- IC (Interstitial Cystitis) / Painful bladder syndrome
- Metabolic Syndrome and Obesity
- Myocardial Infarction
- NDO (Neurogenic Detrusor Overactivity)
- OAB (Overactive Bladder)
- SCI (Spinal Cord Injury)